Essential adaptor by Wells, William A.
In This Issue
JCB • VOLUME 175 • NUMBER 6 • 2006 840
Essential adaptor
R
eceptors keep signaling long after they are endocytosed 
thanks to a variety of adaptor proteins. Now, Teis et al. 
show on page 861 that the loss of p14, a protein that 
helps attach active MAP kinase to endosomes, results in endosome 
positioning defects, cell cycle problems, and death.
Mice lacking p14 died as embryos. Fibroblasts from the embryos 
had normal early endosomes but, compared with wild-type cells, 
twice as many of their late endosomes and lysosomes were located 
far from the nucleus, and degradation of internalized EGF receptor 
was half as effi  cient.
Epidermal-specifi  c deletion of p14 resulted in mice that were 
born alive but died soon after from dehydryation. EGF receptors, 
normally found only in basal cell layers, were not degraded properly 
and were therefore expressed even in suprabasal cell layers. The 
mice had thin skin, apparently because of the reduced proliferation that was evident in vitro for harvested 
keratinocytes. This defect could not be rescued by p14 forced to localize to the plasma membrane, 
suggesting that the endosome localization is necessary to build a fully comptetent signaling complex.
A paper in press at Nature Medicine (authored in collaboration with Teis et al.) identifi  es a hypomorphic 
allele of p14 as the explanation for a familial immunodefi  ciency. Here again, endosome dynamics are 
disturbed, possibly because one of the motors that brings adaptor proteins to endosomes also helps 
localize endosomes. Teis et al. now want to see whether inhibition of endosome-localized MAP kinase 
signaling might be more effective against proliferation-related diseases and have fewer side effects than 
inhibition of all MAP kinase signaling.
M
any cancer cells resort 
to inefﬁ  cient glycoly-
sis for their energy 
but can nevertheless survive, 
even when competing with 
their more energy-efﬁ  cient non-
cancerous neighbors. One ex-
planation, say Pelicano et al. 
(page 913), is that the altered 
metabolism can turn on an Akt 
survival pathway.
Most cells rely primarily 
on the rich energy harvest that 
comes from oxidative phos-
phorylation. But a switch to 
glycolysis can be induced by 
hypoxia, the loss of the tumor 
suppressor p53, expression of 
tumor inducers such as Myc and Ras, or mutation 
of certain mitochondrial enzymes.
Mitochondrial mutation is particularly common 
in cancer cells, which are under metabolic stress 
that generates mutagenic oxidants. Mitochondrial 
DNA is a prime target for these mutations as 
these organelles lack many of the safegard 
mechanisms that prevent and repair damage of 
nuclear DNA.
Pelicano et al. mutated mitochondrial DNA. 
The resultant cells grew better under hypoxic 
conditions and were less sensitive to common 
anticancer drugs. The cells produce high levels of 
NADH, which is normally consumed by oxidative 
phosphorylation, and this altered redox environ-
ment inactivated the PTEN phosphatase. With 
PTEN out of action, its target, Akt, was activated. 
This kinase is known to increase cell survival. In 
hypoxic or toxic conditions, this survival pathway 
may be used in normal cells to keep the cells 
healthy, but cancer cells have used it to survive 
despite their unorthodox metabolism.
When cells with mitochondrial mutations were 
treated to prevent the Akt activation, they once 
more became sensitive to anticancer drugs. Inhibi-
tion of the Akt pathway may also be a promising 
approach in the clinic, although it is not yet clear 
which protein in the Akt pathway would make the 
best target, or which anticancer drugs would make 
the best follow-up treatment.
Late endosomes (red) scatter to the cell periphery when the p14 
adaptor is missing.
Cells die less readily if they have mitochondrial 
mutations (black bars).
Surviving on low energy